| Intervention | NMA OR (95% CrI) | NMA LogOR (95% CrI) | Number of studies providing direct evidence |
|---|---|---|---|
| Carbetocin | 0.141 (0.075, 0.256) | −1.96 (−2.59, −1.363) | - |
| Carboprost | 0.177 (0.078, 0.398) | −1.734 (−2.545, −0.922) | 2 |
| Ergometrine plus oxytocin | 0.219 (0.131, 0.363) | −1.52 (−2.034, −1.012) | 3 |
| Misoprostol plus oxytocin | 0.249 (0.123, 0.505) | −1.39 (−2.094, −0.6832) | - |
| Misoprostol >800 mcg and ≤ 1000 mcg | 0.302 (0.060, 1.457) | −1.196 (−2.807, 0.3764) | - |
| Oxytocin >1 IU and ≤ 5 IU | 0.332 (0.180, 0.603) | −1.104 (−1.716, −0.505) | 4 |
| Oxytocin >5 IU and ≤ 10 IU | 0.372 (0.235, 0.591) | −0.989 (−1.448, −0.527) | 2 |
| Misoprostol >600 mcg and ≤ 800 mcg | 0.384 (0.178, 0.838) | −0.958 (−1.727, −0.177) | 2 |
| Ergometrine | 0.414 (0.240, 0.719) | −0.881 (−1.426, −0.33) | 2 |
| Misoprostol ≤ 600 mcg | 0.451 (0.292, 0.699) | −0.797 (−1.23, −0.358) | 9 |
| Oxytocin > 10 IU | 0.541 (0.231, 1.284) | −0.615 (−1.466, 0.2503) | - |
Results from the random effects NMA. OR<1 favours the intervention (lower risk of additional uterotonics in the intervention arm) with lower numbers indicating greater benefit, OR>1 favours placebo. Abbreviations: OR, odds ratio; CrI, credible interval.
From: Evidence reviews for uterotonics for the prevention of postpartum haemorrhage
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.